Tokuyama (4043) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
13 Jun, 2025Executive summary
Net sales for Q2 FY2024 were ¥165.5B, down 0.3% year-over-year due to the exclusion of Excel Shanon, but operating profit rose 63% to ¥13.9B, driven by lower coal prices, improved manufacturing costs, and strong semiconductor-related sales.
Profit attributable to owners of parent increased 87% to ¥11.6B, supported by higher ordinary profit and extraordinary income from share transfers, cross-shareholding reductions, and gains on sale of investment securities.
Despite market uncertainties, full-year forecasts remain unchanged as business performance is progressing in line with plans.
Financial highlights
Net sales: ¥165.5B (down 0.3% year-over-year); operating profit: ¥13.9B (up 63%).
Ordinary profit: ¥13.6B (up 52%); profit attributable to owners: ¥11.6B (up 87%).
Basic EPS: ¥161.81 (up from ¥86.56 year-over-year); comprehensive income fell 27.6% to ¥8.2B due to negative other comprehensive income.
Cost of sales decreased 6.2% year-over-year, reflecting manufacturing cost improvements.
Cash and cash equivalents at period-end were ¥64.8B, up from ¥61.2B a year earlier.
Outlook and guidance
FY2024 forecast unchanged: net sales ¥352.0B (+3%), operating profit ¥33.0B (+29%), profit attributable to owners ¥25.0B (+41%), EPS ¥347.48.
Growth expected from increased sales of semiconductor-related products and lower manufacturing costs.
Dividend forecast for FY2024 raised to ¥100 per share (from ¥80 previous year), with interim and year-end dividends of ¥50 each.
Latest events from Tokuyama
- Operating profit surged on strong semiconductor sales and acquisitions, despite lower revenue.4043
Q3 202630 Jan 2026 - Operating profit up 37.2% on cost improvements and semiconductor demand; major acquisition completed.4043
Q2 202629 Oct 2025 - Operating profit rose 5.1% despite lower sales, driven by cost improvements and semiconductor demand.4043
Q1 202629 Jul 2025 - Operating profit and net income surged despite lower revenue, with guidance unchanged.4043
Q1 202513 Jun 2025 - Profits and sales are set to reach record highs, with a major healthcare acquisition ahead.4043
Q4 20256 Jun 2025 - Semiconductor and dental materials strength drove profit growth and revised guidance.4043
Q3 20255 Jun 2025